These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 37086978)

  • 1. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
    Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.
    Rosales R; McGovern BL; Rodriguez ML; Leiva-Rebollo R; Diaz-Tapia R; Benjamin J; Rai DK; Cardin RD; Anderson AS; ; Sordillo EM; van Bakel H; Simon V; García-Sastre A; White KM
    Antiviral Res; 2024 Oct; 230():105970. PubMed ID: 39067667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
    Pérez-Vargas J; Lemieux G; Thompson CAH; Désilets A; Ennis S; Gao G; Gordon DG; Schulz AL; Niikura M; Nabi IR; Krajden M; Boudreault PL; Leduc R; Jean F
    Antiviral Res; 2024 May; 225():105869. PubMed ID: 38548023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Epidemiology of SARS-CoV-2 Omicron Sub-Lineages Isolated from Turkish Patients Infected with COVID-19.
    Sayan M; Arikan A; Sanlidag E
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated antigen assays display a high heterogeneity for the detection of SARS-CoV-2 variants of concern, including several Omicron sublineages.
    Osterman A; Krenn F; Iglhaut M; Badell I; Lehner A; Späth PM; Stern M; Both H; Bender S; Muenchhoff M; Graf A; Krebs S; Blum H; Grimmer T; Durner J; Czibere L; Dächert C; Grzimek-Koschewa N; Protzer U; Kaderali L; Baldauf HM; Keppler OT
    Med Microbiol Immunol; 2023 Oct; 212(5):307-322. PubMed ID: 37561226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
    Pochtovyi AA; Kustova DD; Siniavin AE; Dolzhikova IV; Shidlovskaya EV; Shpakova OG; Vasilchenko LA; Glavatskaya AA; Kuznetsova NA; Iliukhina AA; Shelkov AY; Grinkevich OM; Komarov AG; Logunov DY; Gushchin VA; Gintsburg AL
    Vaccines (Basel); 2023 Sep; 11(10):. PubMed ID: 37896937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
    Ohashi H; Hishiki T; Akazawa D; Kim KS; Woo J; Shionoya K; Tsuchimoto K; Iwanami S; Moriyama S; Kinoshita H; Yamada S; Kuroda Y; Yamamoto T; Kishida N; Watanabe S; Hasegawa H; Ebihara H; Suzuki T; Maeda K; Fukushi S; Takahashi Y; Iwami S; Watashi K
    Antiviral Res; 2022 Sep; 205():105372. PubMed ID: 35798223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.
    Pérez-Vargas J; Worrall LJ; Olmstead AD; Ton AT; Lee J; Villanueva I; Thompson CAH; Dudek S; Ennis S; Smith JR; Shapira T; De Guzman J; Gang S; Ban F; Vuckovic M; Bielecki M; Kovacic S; Kenward C; Hong CY; Gordon DG; Levett PN; Krajden M; Leduc R; Boudreault PL; Niikura M; Paetzel M; Young RN; Cherkasov A; Strynadka NCJ; Jean F
    Emerg Microbes Infect; 2023 Dec; 12(2):2246594. PubMed ID: 37555275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
    Pérez-Vargas J; Shapira T; Olmstead AD; Villanueva I; Thompson CAH; Ennis S; Gao G; De Guzman J; Williams DE; Wang M; Chin A; Bautista-Sánchez D; Agafitei O; Levett P; Xie X; Nuzzo G; Freire VF; Quintana-Bulla JI; Bernardi DI; Gubiani JR; Suthiphasilp V; Raksat A; Meesakul P; Polbuppha I; Cheenpracha S; Jaidee W; Kanokmedhakul K; Yenjai C; Chaiyosang B; Teles HL; Manzo E; Fontana A; Leduc R; Boudreault PL; Berlinck RGS; Laphookhieo S; Kanokmedhakul S; Tietjen I; Cherkasov A; Krajden M; Nabi IR; Niikura M; Shi PY; Andersen RJ; Jean F
    Antiviral Res; 2023 Jan; 209():105484. PubMed ID: 36503013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
    Dichtl S; Diem G; Jäger M; Zaderer V; Lupoli G; Dächert C; Muenchhoff M; Graf A; Blum H; Keppler OT; Lass-Flörl C; Weiss G; Wilflingseder D; Posch W
    Antiviral Res; 2023 May; 213():105581. PubMed ID: 36965526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
    Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
    Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
    Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells.
    Saleh MAA; Hirasawa M; Sun M; Gülave B; Elassaiss-Schaap J; de Lange ECM
    Eur J Pharm Sci; 2023 Feb; 181():106345. PubMed ID: 36462547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
    Kiso M; Furusawa Y; Uraki R; Imai M; Yamayoshi S; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):3952. PubMed ID: 37402789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.
    Sil D; Gautam S; Saxena S; Joshi S; Kumar D; Mehta A; Jindal P; Sharma S; Pandey P; Diksha ; Singh A
    Curr Drug Targets; 2024; 25(8):517-525. PubMed ID: 38726782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.